Low serum Fetuin A levels and cardiovascular events in End-Stage Renal Disease (ESRD) patients.

Altavilla,P

Risultato della ricerca: Article

1 Citazione (Scopus)

Abstract

The atherosclerotic Cardiovascular Disease (CVD) is frequently observed in End-Stage Renal Disease (ESRD) patients; according to the hypothesis of non-traditional risk factors for CVD, accelerated atherogenesis in these patients could be linked to both vascular calcification and inflammation. 2-Heremans-Schmid Glycoprotein (AHSG) also known as Fetuin-A, is considered a negative marker of inflammation and represents one of the in vivo circulating calcification modulators; these molecules are proteins working as endogenous inhibitors of Ca×PO4 precipitation and are probably involved in the pathogenesis vascular calcification. Aim of this study is to evaluate the differences in serum Fetuin-A levels between 2 Haemodialysis (HD) patient groups distinguished on the basis of history of cardio and/or cerebrovascular events. All patients took part in clinical data collection and 2 patient groups were identified as no cardiovascular and cardiovascular on the basis of history of cardio and/or cerebrovascular events. Serum Fetuin-A levels were determined using sandwich immunoenzymatic assay, ELISA (Epitope Diagnostics Inc., San Diego, CA, USA). Serum Fetuin-A levels were significantly lower in cardiovascular HD patients than in those without cardiovascular event. The role of Fetuin A in the context of the different pathogenetic moments of atherosclerosis remains unclearly assessed; it would be of some interest to investigate the hypothesis, almost unexplored, of a relationship between low Fetuin A levels and endothelial dysfunction.
Lingua originaleEnglish
pagine (da-a)200-202
Numero di pagine3
RivistaResearch Journal of Medical Sciences
Volume2
Stato di pubblicazionePublished - 2008

Fingerprint

alpha-2-HS-Glycoprotein
Chronic Kidney Failure
Serum
Vascular Calcification
Renal Dialysis
Atherosclerosis
Cardiovascular Diseases
Inflammation
Epitopes
Glycoproteins
Enzyme-Linked Immunosorbent Assay

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cita questo

@article{bcf4d2bf36ee4b8abe46bf4ea65787a3,
title = "Low serum Fetuin A levels and cardiovascular events in End-Stage Renal Disease (ESRD) patients.",
abstract = "The atherosclerotic Cardiovascular Disease (CVD) is frequently observed in End-Stage Renal Disease (ESRD) patients; according to the hypothesis of non-traditional risk factors for CVD, accelerated atherogenesis in these patients could be linked to both vascular calcification and inflammation. 2-Heremans-Schmid Glycoprotein (AHSG) also known as Fetuin-A, is considered a negative marker of inflammation and represents one of the in vivo circulating calcification modulators; these molecules are proteins working as endogenous inhibitors of Ca×PO4 precipitation and are probably involved in the pathogenesis vascular calcification. Aim of this study is to evaluate the differences in serum Fetuin-A levels between 2 Haemodialysis (HD) patient groups distinguished on the basis of history of cardio and/or cerebrovascular events. All patients took part in clinical data collection and 2 patient groups were identified as no cardiovascular and cardiovascular on the basis of history of cardio and/or cerebrovascular events. Serum Fetuin-A levels were determined using sandwich immunoenzymatic assay, ELISA (Epitope Diagnostics Inc., San Diego, CA, USA). Serum Fetuin-A levels were significantly lower in cardiovascular HD patients than in those without cardiovascular event. The role of Fetuin A in the context of the different pathogenetic moments of atherosclerosis remains unclearly assessed; it would be of some interest to investigate the hypothesis, almost unexplored, of a relationship between low Fetuin A levels and endothelial dysfunction.",
keywords = "Fetuin-A, ESRD",
author = "Altavilla,P and Marcello Ciaccio and Daniela Butera and Giulia Bivona and Gaia Chiarello and Antonietta Caruso and Chiara Bellia and {Lo Sasso}, Bruna and Rosachiara Carollo",
year = "2008",
language = "English",
volume = "2",
pages = "200--202",
journal = "Research Journal of Medical Sciences",
issn = "1815-9346",
publisher = "Medwell Publishing",

}

TY - JOUR

T1 - Low serum Fetuin A levels and cardiovascular events in End-Stage Renal Disease (ESRD) patients.

AU - Altavilla,P

AU - Ciaccio, Marcello

AU - Butera, Daniela

AU - Bivona, Giulia

AU - Chiarello, Gaia

AU - Caruso, Antonietta

AU - Bellia, Chiara

AU - Lo Sasso, Bruna

AU - Carollo, Rosachiara

PY - 2008

Y1 - 2008

N2 - The atherosclerotic Cardiovascular Disease (CVD) is frequently observed in End-Stage Renal Disease (ESRD) patients; according to the hypothesis of non-traditional risk factors for CVD, accelerated atherogenesis in these patients could be linked to both vascular calcification and inflammation. 2-Heremans-Schmid Glycoprotein (AHSG) also known as Fetuin-A, is considered a negative marker of inflammation and represents one of the in vivo circulating calcification modulators; these molecules are proteins working as endogenous inhibitors of Ca×PO4 precipitation and are probably involved in the pathogenesis vascular calcification. Aim of this study is to evaluate the differences in serum Fetuin-A levels between 2 Haemodialysis (HD) patient groups distinguished on the basis of history of cardio and/or cerebrovascular events. All patients took part in clinical data collection and 2 patient groups were identified as no cardiovascular and cardiovascular on the basis of history of cardio and/or cerebrovascular events. Serum Fetuin-A levels were determined using sandwich immunoenzymatic assay, ELISA (Epitope Diagnostics Inc., San Diego, CA, USA). Serum Fetuin-A levels were significantly lower in cardiovascular HD patients than in those without cardiovascular event. The role of Fetuin A in the context of the different pathogenetic moments of atherosclerosis remains unclearly assessed; it would be of some interest to investigate the hypothesis, almost unexplored, of a relationship between low Fetuin A levels and endothelial dysfunction.

AB - The atherosclerotic Cardiovascular Disease (CVD) is frequently observed in End-Stage Renal Disease (ESRD) patients; according to the hypothesis of non-traditional risk factors for CVD, accelerated atherogenesis in these patients could be linked to both vascular calcification and inflammation. 2-Heremans-Schmid Glycoprotein (AHSG) also known as Fetuin-A, is considered a negative marker of inflammation and represents one of the in vivo circulating calcification modulators; these molecules are proteins working as endogenous inhibitors of Ca×PO4 precipitation and are probably involved in the pathogenesis vascular calcification. Aim of this study is to evaluate the differences in serum Fetuin-A levels between 2 Haemodialysis (HD) patient groups distinguished on the basis of history of cardio and/or cerebrovascular events. All patients took part in clinical data collection and 2 patient groups were identified as no cardiovascular and cardiovascular on the basis of history of cardio and/or cerebrovascular events. Serum Fetuin-A levels were determined using sandwich immunoenzymatic assay, ELISA (Epitope Diagnostics Inc., San Diego, CA, USA). Serum Fetuin-A levels were significantly lower in cardiovascular HD patients than in those without cardiovascular event. The role of Fetuin A in the context of the different pathogenetic moments of atherosclerosis remains unclearly assessed; it would be of some interest to investigate the hypothesis, almost unexplored, of a relationship between low Fetuin A levels and endothelial dysfunction.

KW - Fetuin-A, ESRD

UR - http://hdl.handle.net/10447/64091

M3 - Article

VL - 2

SP - 200

EP - 202

JO - Research Journal of Medical Sciences

JF - Research Journal of Medical Sciences

SN - 1815-9346

ER -